CN Patent

CN120204220A — 治疗及/或预防纤维性疾病的胺基萘醌化合物

Assigned to Bo Wei Pharmaceutical Biotechnology Co ltd · Expires 2025-06-27 · 1y expired

What this patent protects

本发明涉及治疗及/或预防纤维性疾病的胺基萘醌化合物。本发明涉及如本文中所述式(I)化合物及其有效剂量在预防及/或治疗纤维性疾病中的用途。所述化合物可有效预防及/或治疗纤维性疾病而无细胞毒性或基因毒性。

USPTO Abstract

本发明涉及治疗及/或预防纤维性疾病的胺基萘醌化合物。本发明涉及如本文中所述式(I)化合物及其有效剂量在预防及/或治疗纤维性疾病中的用途。所述化合物可有效预防及/或治疗纤维性疾病而无细胞毒性或基因毒性。

Drugs covered by this patent

Kyprolis (carfilzomib) · Amgen

Patent Metadata

Patent number: CN120204220A
Jurisdiction: CN
Classification: —
Expires: 2025-06-27
Drug substance claim: No
Drug product claim: No
Assignee: Bo Wei Pharmaceutical Biotechnology Co ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.